"During fiscal 2008, we strengthened our competitive position and built upon our private label distribution network culminating in an outstanding fourth quarter in which we posted more than $820,000 in revenue," said Michael L. Krall, President and CEO of PURE Bioscience. "PURE established and continues to make important strides toward finalizing additional contracts with major market players for the integration of SDC into third party products, including a new partnership with a respected leader for the development of FDA-regulated SDC products.
"It is important to note that virtually all of our initiatives within major markets and with world-class partners remain under continuing discussion and negotiation. Furthermore, we have identified a number of large new markets for SDC for agriculture and water applications, particularly within growing developing countries around the world. Finally, regulatory and legislative changes, as well as consumer and competitive pressures are driving companies to explore, review and adopt 'green' and environmentally favorable solutions like SDC, the first new anti-microbial approved by the EPA in over thirty years.
"The size of potential markets and the breadth of applications for our technology continue to grow," concluded Mr. Krall. "From our presentations and meetings across various sectors and country borders, with current, pending and potential industry-leading partners, I have never been more encouraged and confident in the soundness of our strategy, the focus of our execution and the enormous opportunities for growth and success for PURE Bioscience."
The Company has scheduled a conference call t
|SOURCE PURE Bioscience|
Copyright©2008 PR Newswire.
All rights reserved